Bright Minds Biosciences Inc.
Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
About
CEO
Mr. Ian McDonald
Employees
0
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
19 Vestry Street, New York, NY 10013, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Dec 30, 2024 | -0.60 | -0.17 | 0.43 | -71.67% |
| Dec 29, 2021 | — | -0.24 | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Sep 2025)
|
Next Year
(Sep 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 1 | 1 | 1 |
| Average estimate | — | -0.18 | -0.77 | -1.50 |
| Low estimate | — | -0.18 | -0.77 | -1.50 |
| High estimate | — | -0.18 | -0.77 | -1.50 |
| Last year EPS | — | — | — | -0.77 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year (Sep 2025)
—
Next year (Sep 2026)
-137.060%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 1.18M | 5.00M | 12.18M | 6.31M | 354,852 |
| Selling general and admin | 1.45M | 2.20M | 2.55M | 2.29M | 114,506 |
| Other operating expenses | 197,186 | 186,651 | 243,079 | 181,743 | 5,451 |
| Operating income | -2.82M | -7.39M | -14.98M | -8.79M | -474,809 |
| Non operating interest income | |||||
| Income | 30,133 | — | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | -9,312 | 14,189 | 10,151 | 154,099 | -5,451 |
| Pretax income | -2.80M | -7.37M | -14.96M | -8.65M | -480,377 |
| Tax provision | — | — | — | — | — |
| Net income | -2.80M | -7.37M | -14.96M | -8.65M | -480,377 |
| Basic EPS | — | -1.98 | -6.06 | -4.82 | -0.38 |
| Diluted EPS | — | -1.98 | -6.06 | -4.82 | -0.38 |
| Basic average shares | — | 5.33M | 3.54M | 2.57M | 1.84M |
| Diluted average shares | — | 5.33M | 3.54M | 2.57M | 1.84M |
| EBITDA | -2.74M | -7.33M | -14.98M | -8.94M | -474,809 |
| Net income from continuing op. | -2.80M | -7.37M | -14.96M | -8.65M | -480,377 |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 6.10M | 6.88M | 12.09M | 20.04M | 880,216 |
| Current assets | |||||
| Cash | 5.63M | 6.66M | 11.54M | 19.67M | 799,929 |
| Cash equivalents | 86,250 | 86,250 | 86,250 | 86,250 | — |
| Cash and cash equivalents | 5.72M | 6.75M | 11.63M | 19.76M | 799,929 |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | 41,261 | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 216,628 | 27,692 | 164,429 | 168,207 | 78,287 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Non current assets | |||||
| Properties | — | — | 138,863 | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | 117,658 | 66,413 | 138,863 | — | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | — | — | — | 2,000 | 2,000 |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | — | — | — | — | — |
| Total liabilities | 568,259 | 280,856 | 1.54M | 638,573 | 150,923 |
| Current liabilities | |||||
| Accounts payable | 407,548 | 182,307 | 1.25M | 596,573 | 138,423 |
| Accrued expenses | 41,751 | 25,000 | 158,177 | 42,000 | 12,500 |
| Short term debt | 79,384 | 73,549 | 67,928 | — | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 39,576 | — | 71,983 | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 35.42M | 33.91M | 32.24M | 27.08M | 980,661 |
| Retained earnings | -34.35M | -31.55M | -24.17M | -9.21M | -559,094 |
| Other shareholders equity | 4.01M | 3.40M | 2.48M | 1.57M | 161,300 |
| Total shareholders equity | 5.54M | 6.60M | 10.54M | 19.40M | 729,293 |
| Additional paid in capital | — | — | — | — | — |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -2.80M | -7.37M | -14.96M | -8.65M | -480,377 |
| Depreciation | 73,357 | 72,450 | 6,037 | — | — |
| Deferred Taxes | — | — | — | — | — |
| Stock-Based Compensation | 839,771 | 1.15M | 875,056 | 880,615 | 161,300 |
| Other Non-Cash Items | 8,945 | 19,750 | 29,423 | 368,550 | — |
| Accounts Receivable | -13,243 | 118,798 | -45,633 | -110,146 | — |
| Accounts Payable | — | — | — | — | — |
| Other Assets & Liabilities | — | — | 2,173 | — | — |
| Operating Cash Flow | -1.89M | -6.01M | -14.10M | -7.51M | -319,077 |
| Investing Activities | |||||
| Capital Expenditures | — | — | — | — | — |
| Net Intangibles | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — |
| Financing Activities | |||||
| Long-Term Debt Issuance | — | — | — | — | — |
| Long-Term Debt Payments | -89,730 | -86,112 | -7,162 | — | — |
| Other Financing Charges | — | -26,976 | -799,979 | -1.81M | — |
| Financing Cash Flow | 810,270 | 1.10M | 3.23M | 25.94M | 1.01M |
| Other Cash Details | |||||
| End Cash Position | 5.72M | 6.75M | 11.63M | 19.76M | 799,929 |
| Income Tax Paid | — | — | — | — | — |
| Interest Paid | — | — | — | — | — |
| Free Cash Flow | -1.85M | -7.02M | -13.59M | -7.32M | -288,392 |
Error: Invalid format in Holders JSON file.
Article
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety.
Jan 26, 2025
Article
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an advisory capacity.
Jan 7, 2025
Article
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
Nov 13, 2024
